Investigating how MyD88 signaling affects inflammation and Alzheimer's disease
Role of MyD88 signaling in systemic inflammation and Alzheimer disease
This study is looking at how a specific signaling process related to inflammation might affect Alzheimer's disease, especially in older adults, to find new ways to help prevent or treat the condition.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Illinois at Chicago NIH-funded |
| Lab location | 1 site (Chicago, UNITED STATES) |
| Project ID | NIH-11075893 on NIH RePORTER |
What this research studies
This research explores the role of MyD88 signaling in the context of systemic inflammation and its impact on Alzheimer's disease (AD). It focuses on understanding how chronic inflammation, particularly in aging populations, contributes to the development and progression of AD. The study utilizes animal models to investigate the molecular mechanisms behind inflammation and its relationship with amyloid plaques and tau protein aggregates in the brain. By identifying these pathways, the research aims to uncover potential therapeutic targets for preventing or treating AD.
Who could benefit from this research
Good fit: Ideal candidates for this research are older adults who are at risk for Alzheimer's disease due to age-related factors or chronic inflammation.
Not a fit: Patients with early-onset familial Alzheimer's disease may not benefit from this research as it primarily focuses on late-onset AD mechanisms.
Why it matters
Potential benefit: If successful, this research could lead to new strategies for preventing or treating Alzheimer's disease by targeting inflammation.
How similar studies have performed: Previous research has shown that targeting inflammation can be beneficial in other neurodegenerative diseases, suggesting potential success for this approach in Alzheimer's disease.
Where this research is happening
Chicago, UNITED STATES
- University of Illinois at Chicago — Chicago, United States (Active)
Researchers
- Principal investigator: Fukuchi, Ken-Ichiro — University of Illinois at Chicago
- Study coordinator: Fukuchi, Ken-Ichiro
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.